UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES AND EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): June 26, 2015
AVALANCHE BIOTECHNOLOGIES, INC.
(Exact Name of Registrant as Specified in its Charter)
| Delaware | 001-36579 | 20-5258327 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File No.) |
(I.R.S. Employer Identification No.) |
1035 O’Brien Drive, Suite A
Menlo Park, CA 94025
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (650) 272-6269
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a–12 under the Exchange Act (17 CFR 240.14a–12) |
| ¨ | Pre-commencement communication pursuant to Rule 14d–2(b) under the Exchange Act (17 CFR 240.14d–2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e–4(c) under the Exchange Act (17 CFR 240.13e–4(c)) |
| Item 5.07 | Submission of Matters to a Vote of Security Holders |
On June 26, 2015, Avalanche Biotechnologies, Inc. (the “Company”) held its 2015 Annual Meeting of Stockholders. A total of 18,182,992 shares of the Company’s common stock were represented in person or by valid proxy, and the stockholders voted on two proposals. The final results for the votes regarding each proposal are set forth below:
1. Election of two Class I directors, Thomas W. Chalberg, Jr., Ph.D. and Paul D. Wachter, each to serve a three-year term, which will expire at the 2018 Annual Meeting of Stockholders, or until such time as their respective successors have been elected and qualified.
| Nominees |
Shares For |
Shares Withheld |
Broker Non-Votes |
|||||||||
| Thomas W. Chalberg, Jr., Ph.D. |
14,448,262 | 1,770,704 | 1,964,026 | |||||||||
| Paul D. Wachter |
14,432,578 | 1,786,388 | 1,964,026 | |||||||||
2. Ratification of the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2015.
| Shares For |
Shares Against |
Shares Abstaining |
Broker Non-Votes | |||
| 18,162,034 |
19,998 | 960 | — |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AVALANCHE BIOTECHNOLOGIES, INC. | ||||||
| Date: June 29, 2015 | By: | /s/ Hans P. Hull | ||||
| Hans P. Hull | ||||||
| Senior Vice President, Business Operations and Corporate Secretary | ||||||